R. Scott Struthers, Ph.D.

Founder & Chief Executive Officer


R. Scott Struthers, Ph.D., is our co-founder and has served as our President and Chief Executive Officer since December 2008. Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc., from 1998 to 2008. At Neurocrine, he initiated and led the effort to discover and develop orally active, nonpeptide GnRH antagonists, including elagolix. Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets. Between 1992 to 1995 he led contract research efforts at Biosym Technologies to develop and apply computational tools for drug discovery.

In 2021, Dr. Struthers co-founded and serves as board chair at Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for oncology indications. In addition, he is a member of the board of directors of the San Diego Entrepreneurs Exchange, a nonprofit organization that provides resources for early-stage start-ups, which he co-founded in [2009.]

Struthers, R.S., Tanaka, G., Koerber, S.C., Solmajer, T., Baniak, E.L., Gierasch, L.M., Vale, W., Rivier, J. and Hagler, A.T. (1990), Design of biologically active, conformationally constrained GnRH antagonists. Proteins, 8: 295-304. doi:10.1002/prot.340080403

Struthers, R., Vale, W., Arias, C. et al. Somatotroph hypoplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant. Nature 350, 622–624 (1991). doi:10.1038/350622a0

Struthers, R., Vale, W., Arias, C. et al. Somatotroph hypoplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant. Nature 350, 622–624 (1991). doi:10.1038/350622a0